Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.61 USD | +0.04% | +7.96% | -22.17% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.17% | 2.28B | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Insider Trends: Intellia Therapeutics Insider Reports Option Conversion Extending 90-Day Buying Trend